Prescription Drug Recall: Atorvastatin Calcium Tablets for Manufacturing Deviations
Accord Healthcare is recalling Atorvastatin Calcium 10 mg tablets distributed in the United States, Puerto Rico, and Canada following FDA inspection findings of manufacturing deviations.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses, hospitalizations, or injuries. The hazard is theoretical manufacturing deviations without a named specific quality defect. Per the editorial rubric, when no illnesses are reported and the hazard is theoretical, the score is at most 3. This precautionary recall warrants a Moderate classification.
Plain-English summary
Accord Healthcare, Inc. is recalling Atorvastatin Calcium Tablets USP, 10 mg, Rx Only, distributed in the United States, Puerto Rico, and Canada. A total of 256,106 bottles are affected, covering multiple batch numbers with expiration dates between March 31, 2023 and June 30, 2024.
The recall was initiated following an FDA inspection that identified Current Good Manufacturing Practice (CGMP) deviations. CGMP violations indicate that the manufacturer's quality control and production processes did not meet FDA regulatory standards for pharmaceutical manufacturing.
Consumers holding affected bottles of Atorvastatin Calcium 10 mg should verify their batch number against the recall records and contact their pharmacy or healthcare provider for guidance on obtaining replacement medication.
The recalled product
- Product
- ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM)
- Brand
- ATORVASTATIN CALCIUM
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug
- Hazard
- Affected units
- 256,106
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a)R2100455
- Exp. Date 3/31/2023
- R2200274
- Exp. Date 1/31/2024
- R2200700
- Exp. Date 5/31/2024
- b) R2101342
- R2101343
- R2101476
- Exp. Date 9/30/2023
- R2101364
- R2101365
- R2101366
- R2101367
- Exp. Date 10/31/2023
- R2101612
- R2101613
- R2101614
- Exp. Date 11/30/2023
- R2200222
UPCs (2)
- 316729044158
- 316729044172
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 67 recalled by Accord Healthcare, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same brand · ATORVASTATIN CALCIUM
- ModerateAtorvastatin 40 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 10 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 20 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 80 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- HighBiocon Pharma atorvastatin calcium tablets recalled for failed dissolution specifications
FDA (Drugs) · 2025-04-09
Same manufacturer · Accord Healthcare, Inc.
See all →- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same hazard · manufacturing deviation
See all →- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateiVIZIA Dry Eye Lubricant Drops Recalled for Sterility Assurance
FDA (Drugs) · 2026-05-06
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29